search
Back to results

A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
High dose of Micardis®, once daily
Low dose of Micardis®, once daily
Low dose of COZAAR®, once daily
High dose of COZAAR®, once daily
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP). The manual cuff value is calculated as the mean of three seated measurements taken two minutes apart, after the patient has been seated quietly for 5 minutes
  • A 24-mean DBP of ≥ 85 mmHg at Visit 7 as measured by ABPM
  • Age 18 years or older
  • Ability to stop current antihypertensive therapy without risk to the patient (investigator's discretion)
  • Ability to provide written informed consent

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who:

    • are not surgically sterile; and/or
    • are nursing
    • are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives
  • Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥ 110 mmHg during any visit of the placebo run-in period
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • Serum glutamate-pyruvate-transaminase (alanine aminotransferase) or serum glutamate-oxaloacetate-transaminase (aspartate aminotransferase) greater than two times the upper limit of normal
    • Serum creatinine > 2.3 mg/dL
  • Clinically relevant sodium depletion, hyperkalemia, or hypokalemia
  • Uncorrected volume depletion
  • Primary aldosteronism
  • Biliary obstructive disorders
  • Known or suspected secondary hypertension
  • Hereditary fructose intolerance
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
  • Congestive heart failure (NYHA functional class congestive heart failure (CHF) class III-IV)
  • Unstable angina within the past three months
  • Stroke within the past six months
  • Myocardial infarction or cardiac surgery within the past three months
  • Percutaneous transluminal coronary angioplasty (PTCA) within the past three months
  • History of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
  • Patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an HbA1c ≥ 10%
  • Known drug or alcohol dependency within the past 6 months
  • Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
  • Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 ante meridien (AM)
  • Patients receiving any investigational therapy within one month of signing the informed consent form
  • Known hypersensitivity to any component of the formulations
  • Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Active Comparator

    Active Comparator

    Arm Label

    Low dose of Micardis®

    High dose of Micardis®

    Low dose of COZAAR®

    High dose of COZAAR®

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change from baseline in mean diastolic blood pressure
    Measured during the last 6 hours of the 24-hour dosing interval using ABPM

    Secondary Outcome Measures

    Change from baseline in mean systolic blood pressure
    Measured during the last 6 hours of the 24-hour dosing interval using ABPM
    Changes from baseline in diastolic and systolic blood pressure
    Measured during other times of the 24-hour ABPM profile (e.g. 24-hour mean, morning mean, daytime mean and nighttime mean)
    Changes from baseline in mean seated trough diastolic blood pressure and systolic blood pressure
    Triplicate measurement in two minute intervals after 5 minutes of rest, in seated position using sphygmomanometer
    Assessment of responder rates on ABPM
    Assessment of responder rates on trough cuff blood pressure

    Full Information

    First Posted
    July 24, 2014
    Last Updated
    July 24, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02200640
    Brief Title
    A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
    Official Title
    A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    March 2000 (undefined)
    Primary Completion Date
    December 2000 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan 40-80 mg) and COZAAR® (losartan 50-100 mg) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM after 8-weeks treatment. Secondary objectives include evaluations of: 1) change from baseline in mean systolic blood pressure (SBP) during the last 6 hours of the 24-hour dosing interval as measured by ABPM, 2) changes from baseline in SBP and DBP during other periods during the 24-hour ABPM profile, 3) changes from baseline in mean seated trough SBP and DBP as measured by manual cuff sphygmomanometer, and 4) responder rates based on both ABPM and trough cuff blood pressure

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    333 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Low dose of Micardis®
    Arm Type
    Experimental
    Arm Title
    High dose of Micardis®
    Arm Type
    Experimental
    Arm Title
    Low dose of COZAAR®
    Arm Type
    Active Comparator
    Arm Title
    High dose of COZAAR®
    Arm Type
    Active Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    High dose of Micardis®, once daily
    Other Intervention Name(s)
    Telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Low dose of Micardis®, once daily
    Other Intervention Name(s)
    Telmisartan
    Intervention Type
    Drug
    Intervention Name(s)
    Low dose of COZAAR®, once daily
    Other Intervention Name(s)
    Losartan
    Intervention Type
    Drug
    Intervention Name(s)
    High dose of COZAAR®, once daily
    Other Intervention Name(s)
    Losartan
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Change from baseline in mean diastolic blood pressure
    Description
    Measured during the last 6 hours of the 24-hour dosing interval using ABPM
    Time Frame
    Up to 8 weeks after start of treatment
    Secondary Outcome Measure Information:
    Title
    Change from baseline in mean systolic blood pressure
    Description
    Measured during the last 6 hours of the 24-hour dosing interval using ABPM
    Time Frame
    Up to 8 weeks after start of treatment
    Title
    Changes from baseline in diastolic and systolic blood pressure
    Description
    Measured during other times of the 24-hour ABPM profile (e.g. 24-hour mean, morning mean, daytime mean and nighttime mean)
    Time Frame
    Up to 8 weeks after start of treatment
    Title
    Changes from baseline in mean seated trough diastolic blood pressure and systolic blood pressure
    Description
    Triplicate measurement in two minute intervals after 5 minutes of rest, in seated position using sphygmomanometer
    Time Frame
    Up to 8 weeks after start of treatment
    Title
    Assessment of responder rates on ABPM
    Time Frame
    Baseline, 8 weeks after start of treatment
    Title
    Assessment of responder rates on trough cuff blood pressure
    Time Frame
    Baseline up to 8 weeks after start of treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure of ≥ 95 mmHg and ≤ 109 mmHg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP). The manual cuff value is calculated as the mean of three seated measurements taken two minutes apart, after the patient has been seated quietly for 5 minutes A 24-mean DBP of ≥ 85 mmHg at Visit 7 as measured by ABPM Age 18 years or older Ability to stop current antihypertensive therapy without risk to the patient (investigator's discretion) Ability to provide written informed consent Exclusion Criteria: Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period) who: are not surgically sterile; and/or are nursing are of child-bearing potential and are NOT practicing acceptable means of birth control, do NOT plan to continue using this method throughout the study and do NOT agree to submit to periodic pregnancy testing during participation in studies of ≥ 3-months duration. Acceptable methods of birth control include intrauterine device (IUD), oral, implantable or injectable contraceptives Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥ 110 mmHg during any visit of the placebo run-in period Hepatic and/or renal dysfunction as defined by the following laboratory parameters: Serum glutamate-pyruvate-transaminase (alanine aminotransferase) or serum glutamate-oxaloacetate-transaminase (aspartate aminotransferase) greater than two times the upper limit of normal Serum creatinine > 2.3 mg/dL Clinically relevant sodium depletion, hyperkalemia, or hypokalemia Uncorrected volume depletion Primary aldosteronism Biliary obstructive disorders Known or suspected secondary hypertension Hereditary fructose intolerance Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney Congestive heart failure (NYHA functional class congestive heart failure (CHF) class III-IV) Unstable angina within the past three months Stroke within the past six months Myocardial infarction or cardiac surgery within the past three months Percutaneous transluminal coronary angioplasty (PTCA) within the past three months History of angioedema Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve Patients with insulin-dependent diabetes mellitus whose diabetes hast not been stable and controlled for at least the past three months as defined by an HbA1c ≥ 10% Known drug or alcohol dependency within the past 6 months Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 ante meridien (AM) Patients receiving any investigational therapy within one month of signing the informed consent form Known hypersensitivity to any component of the formulations Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com
    Description
    Related Info

    Learn more about this trial

    A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)

    We'll reach out to this number within 24 hrs